Acceleron Pharma Inc
[XLRN]
$10,932 MM MCap
Acceleron focuses its research, development, and commercialization efforts in pulmonary and hematologic diseases. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary hypertension, currently in Phase 3 development, as well as ACE-1334 in SSc-ILD, which will be in the clinic by year-end. In hematology, REBLOZYL® (luspatercept-aamt), part of a global collaboration partnership with BMS, is the first and only erythroid maturation agent approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders. [more information]